MTE #32: Bridging to Transplant in Hepatocellular Carcinoma—Immunotherapy, Locoregional Therapy, or Both? (Ticketed)

Sun, Nov 8, 2026 · 12:45–1:30 PM MST Convention Center: Room 1D, Colorado Convention Center

About this session

Immune checkpoint inhibitors (ICIs) have reshaped the treatment paradigm of hepatocellular carcinoma (HCC), delivering improvements in tumor responses and survival benefits in those with advanced disease. Simultaneously, liver transplantation remains the most effective curative strategy for selected perons with HCC.